# Debiopharm

Source: https://onco.cc/companies/debiopharm/  
OnCo record `debiopharm` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Debiopharm is the private Swiss developer of the WEE1 inhibitor zedoresertib (Debio 0123) and of dual-payload ADC research.

## Summary

Zedoresertib is a brain-penetrant, selective WEE1 inhibitor in phase 1/2 as monotherapy and with carboplatin (platinum-resistant ovarian) or with the PKMYT1 inhibitor lunresertib in CCNE1/FBXW7/PPP2R1A-altered tumours (first data AACR 2026). Debiopharm also presented dual-payload ADC and AI-biomarker work at AACR 2026.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Lausanne
- Type: biotech
- Website: https://www.debiopharm.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Debiopharm
- Debiopharm AACR 2026: https://www.debiopharm.com/drug-development/press-releases/debiopharm-to-unveil-new-pre-clinical-and-clinical-research-advances-in-ddr-inhibition-dual-payload-adcs-and-ai-driven-biomarkers-at-aacr-2026/

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Dual-payload ADC](https://onco.cc/technologies/dual-payload-adc/), [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/)
- targets: [TP53](https://onco.cc/targets/tp53/), [WEE1](https://onco.cc/targets/wee1/)
- trials: [A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma](https://onco.cc/trials/nct05765812/), [A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)](https://onco.cc/trials/nct06969430/), [TrilynX](https://onco.cc/trials/trilynx/)
- drugs: [Xevinapant](https://onco.cc/drugs/xevinapant/)

---
JSON: https://onco.cc/api/v1/entities/debiopharm.json